Novo Nordisk is to develop an oral formulation of insulin with US biotech company Emisphere Technologies. The New Jersey-based biotech …
Trio become latest Symbiosis commercial additions
UK immunoglobulin supply faces growing pressure, report warns
How will biomarker-led diagnostics reshape respiratory medicine?

